Daphne Koller, insitro CEO (Stefan Wermuth/Bloomberg via Getty Images)

May 8, 2025 02:22 PM EDT

AI-focused biotech insitro cuts 22% of staff, citing 'tumultuous market'

Andrew Dunn

Senior Biopharma Correspondent

The AI-focused biotech insitro has laid off 22% of its workforce, the company said in a Thursday statement.

Founded in 2018 by CEO Daphne Koller …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

Novo Nordisk ‘strongly’ urges against pharma tariffs as comments flood in

A new dawn for psychedelics? Compass could be the first to find out

Weeks after TIGIT fail, iTeos decides to wind down

sponsored

From weeks to days: how Aizon Intelligent Agents transform pharma validation